Preliminary Assessment of Cognitive Function in Breast Cancer Patients Treated with Tamoxifen

  title={Preliminary Assessment of Cognitive Function in Breast Cancer Patients Treated with Tamoxifen},
  author={Annlia Paganini-Hill and Linda J. Clark},
  journal={Breast Cancer Research and Treatment},
AbstractBackground. Tamoxifen is an anti-estrogen used in the treatment of breast cancer and to reduce the incidence of breast cancer in high risk women. Although the brain is an estrogen target organ and several studies have found a beneficial effect of estrogen on cognitive function, the effect of tamoxifen on cognition has not been reported. Therefore, we initiated a follow-up study of women who had participated in a study of breast cancer to assess the effect of tamoxifen treatment on… 

Cognitive effects of Tamoxifen in pre-menopausal women with breast cancer compared to healthy controls

The results of this exploratory study suggest that at least in pre-menopausal women, TAM may exert a widespread negative influence on cognitive abilities.

The effects of hormone therapy on cognition in breast cancer

Neuropsychological functioning in postmenopausal breast cancer patients treated with tamoxifen or exemestane after AC-chemotherapy: Cross-sectional findings from the neuropsychological TEAM-side study

The findings show that sequential treatment of AC-chemotherapy and hormonal therapy in postmenopausal, primary BC is associated with lower test scores for certain cognitive functions, and provide indications for possibly distinctive associations for different types of hormonal treatment.

Does hormone therapy for the treatment of breast cancer have a detrimental effect on memory and cognition? A pilot study

The results showed specific impairments in processing speed and verbal memory in women receiving hormonal therapy for the treatment of breast cancer.

Memory impairments with adjuvant anastrozole versus tamoxifen in women with early-stage breast cancer

Cognitive function in women with early-stage breast cancer who received tamoxifen with those who received anastrozole therapy was compared in a cross-sectional study to validate and confirm the changes in cognitive function associated with hormone therapy for breast cancer.

Effects of adjuvant treatment on cognitive function in women with early breast cancer.

Cognitive Sequelae of Endocrine Therapy for the Treatment of Breast Cancer

The results of two studies converged to suggest a specific adverse effect of ET on verbal memory, a domain that has established clinical utility as an early predictor of dementia and should be considered in clinical decision making.

Cognitive function after adjuvant treatment for early breast cancer: a population-based longitudinal study

The results do not support that adjuvant chemotherapy is associated with cognitive side effects in breast cancer patients, and patients receiving chemotherapy or tamoxifen were up to three times more likely than controls to rate themselves as impaired at 6 months.

Neurocognitive Performance in Breast Cancer Survivors Exposed to Adjuvant Chemotherapy and Tamoxifen

Examination of neurocognitive functioning among breast cancer survivors exposed to systemic adjuvant chemotherapy suggested that systemic chemotherapy, especially in combination with tamoxifen, can have adverse yet subtle effects on cognitive functioning.



Eye problems in breast cancer patients treated with tamoxifen

It is suggested that five or more years of tamoxifen use increases risk of cataracts, and healthy women considering tamoxIFen use to reduce risk of breast cancer should be advised of the possibility ofCataract development.

Impairment of cognitive function in women receiving adjuvant treatment for high-risk breast cancer: high-dose versus standard-dose chemotherapy.

High-dose chemotherapy appears to impair cognitive functioning more than standard- dose chemotherapy, and central nervous system toxicity may be a dose-limiting factor in high-dose cancer treatment regimens.

Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study.

Tamoxifen decreases the incidence of invasive and noninvasive breast cancer and its use as a breast cancer preventive agent is appropriate in many women at increased risk for the disease.

Clinical recognition and management of depression in node negative breast cancer patients treated with tamoxifen

It is concluded that clinical depression as a side effect of tamoxifen therapy may be more common than previously believed and should be further rigorously investigated to confirm or deny the clinical impressions.

Estrogen therapy in postmenopausal women: effects on cognitive function and dementia.

There are plausible biological mechanisms by which estrogen might lead to improved cognition, reduced risk for dementia, or improvement in the severity of dementia, but large placebo-controlled trials are required to address estrogen's role in prevention and treatment of Alzheimer disease and other dementias.

Adjuvant tamoxifen therapy for early stage breast cancer and second primary malignancies. Stockholm Breast Cancer Study Group.

The endometrium and gastrointestinal organs may be target sites for tamoxifen-induced carcinogenesis in humans and the increased incidence of colorectal and stomach cancers reported here should be regarded as tentative until supported by long-term data from a larger number of tamoxIFen trials.

The effect of estrogen replacement therapy on cognitive function in women: a critical review of the literature.

Neuropsychological assessment of cognitive functioning following chemotherapy for breast cancer

It is suggested that cognitive impairment may follow conventional adjuvant chemotherapy treatment and warrant replication with a controlled and more rigorous longitudinal design.

The control of breast cancer: the role of tamoxifen.

Tamoxifen has a particularly valuable role in developing countries in which the incidence of breast cancer is increasing as the average age of the population increases and in which control is substantially more difficult with mass mammography screening.

Effect of hormone replacement therapy on breast cancer risk: estrogen versus estrogen plus progestin.

This study provides strong evidence that the addition of a progestin to HRT enhances markedly the risk of breast cancer relative to estrogen use alone, and has important implications for the risk-benefit equation for HRT in women using CHRT.